scholarly journals Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with diabetes: A population-based cohort study

2020 ◽  
Author(s):  
Chen-Yi Wu ◽  
Chun-Ying Wu ◽  
Chung-Pin Li ◽  
Yiing-Jenq Chou ◽  
Yi-Hsian Lin ◽  
...  
Keyword(s):  
Cohort Study ◽  
Bullous Pemphigoid ◽  
Cumulative Incidence ◽  
Dipeptidyl Peptidase ◽  
Diabetic Patients ◽  
Diabetes Diagnosis ◽  
Dipeptidyl Peptidase 4 ◽  
Duration Of Diabetes ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Diabetes Patients

Abstract Background Higher bullous pemphigoid (BP) risk has been reported to be associated with dipeptidyl peptidase 4 inhibitor (DPP4i). However, large-scale studies to investigate the association between BP and DPP4i treatment are limited. The aim of this study is to examine the association between BP risk and DPP4i treatment in diabetes patients. Methods We conducted a nationwide cohort study based on the Taiwan National Health Insurance Database between 2000 and 2015. 124,619 diabetic patients who were receiving DPP4i therapy were matched 1: 1 with diabetic patients who had never received DPP4i by age, sex, duration of diabetes, insulin usage, and propensity score-matching of comorbidities. Results Of the 124,619 diabetes patients in the two groups, the mean age at diabetes diagnosis was 52.4 ± 10.9 years, with a mean duration of diabetes of 6.0 ± 3.9 years. After adjusting for competing mortality risk, the 6-year cumulative incidence of BP in the DPP4i-treated cohort was significantly higher than that in the non-DPP4i group (0.74 per 1000; 95% confidence interval [CI]: 0.51–1.05 vs 0.38 per 1000; 95% CI: 0.26–0.53, P = .001). The DPP4i and insulin-treated group had the highest 6-year cumulative incidence for BP (0.93; 95% CI: 0.54–1.54 per 1000). Modified Cox regression analysis revealed that DPP4i treatment (HR: 2.15, 95% CI: 1.18–3.91, P = 0.01), age (HR: 1.06, P < .001), renal disease (HR: 2.32, P < .001), and metformin user (HR: 1.93, P = 0.006) were associated with increased BP risk. Conclusion DPP4i users had a 2.2-fold increase in the risk of BP, and the risk was the highest in those with concomitant use of DPP4i and insulin. The use of DPP4is as anti-diabetic medications must be monitored carefully and may be replaced by other anti-diabetic medications in BP patients.

scholarly journals Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two Cases

Diabetes Care ◽  
2011 ◽  
Vol 34 (8) ◽  
pp. e133-e133 ◽  
Author(s):  
Efi Pasmatzi ◽  
Alexandra Monastirli ◽  
John Habeos ◽  
Sophia Georgiou ◽  
Dionysios Tsambaos
Keyword(s):  
Bullous Pemphigoid ◽  
Dipeptidyl Peptidase ◽  
Diabetic Patients ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors

Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population‐based, cohort study in Taiwan

2019 ◽  
Vol 47 (3) ◽  
pp. 245-250 ◽  
Author(s):  
Chih‐Tsung Hung ◽  
Jhih‐Syuan Liu ◽  
Cheng‐Yi Cheng ◽  
Chi‐Hsiang Chung ◽  
Chien‐Ping Chiang ◽  
...  
Keyword(s):  
Cohort Study ◽  
Bullous Pemphigoid ◽  
Dipeptidyl Peptidase ◽  
Population Based ◽  
Dipeptidyl Peptidase 4 ◽  
Increased Risk ◽  
Dipeptidyl Peptidase 4 Inhibitors

Association Between Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Cohort Study

2020 ◽  
Vol 111 (3) ◽  
pp. 249-253 ◽  
Author(s):  
J. Magdaleno-Tapial ◽  
C. Valenzuela-Oñate ◽  
Á. Esteban Hurtado ◽  
J.M. Ortiz-Salvador ◽  
D. Subiabre-Ferrer ◽  
...  
Keyword(s):  
Cohort Study ◽  
Bullous Pemphigoid ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors

scholarly journals The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Vaia Lambadiari ◽  
Aikaterini Kountouri ◽  
Foteini Kousathana ◽  
Emmanouil Korakas ◽  
Georgios Kokkalis ◽  
...  
Keyword(s):  
Bullous Pemphigoid ◽  
Prospective Observational Study ◽  
Dipeptidyl Peptidase ◽  
Dermatology Department ◽  
Steroid Administration ◽  
Dipeptidyl Peptidase 4 ◽  
Increased Risk ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
A Prospective Study

Abstract Background Bullous pemphigoid is the most common bullous chronic autoimmune skin disease. Recent studies have suggested dipeptidyl-peptidase 4 inhibitors as possible predisposing agents of bullous pemphigoid. The objective of our study was to prospectively estimate the association between gliptins and the development of bullous pemphigoid. Methods We conducted a prospective study which included all patients diagnosed with biopsy-proven bullous pemphigoid in the Dermatology Department of our hospital between April 1, 2009 and December 31,2019. The diagnosis of bullous pemphigoid was based on specific clinical, histological and immunological features. Results Overall 113 consecutive patients (age 75 ± 13 years, 62 females) with the diagnosis of bullous pemphigoid were enrolled. Seventy-six patients (67.3%) suffered from type 2 Diabetes and 52 (46%) were treated with dipeptidyl-peptidase 4 inhibitors. The most frequent prescribed gliptin was vildagliptin, being administered to 45 cases (39.8% of total patients enrolled, 86.5% of the patients treated with gliptins). Gliptins were withdrawn immediately after the diagnosis of bullous pemphigoid, which together with steroid administration led to remission of the rash. Conclusions This study revealed that treatment with dipeptidyl-peptidase 4 inhibitors, especially vildagliptin, is significantly associated with an increased risk of bullous pemphigoid development.

Association of Dipeptidyl Peptidase-4 Inhibitor Use and Amyloid Burden in Diabetic Patients With AD-Related Cognitive Impairment

Neurology ◽  
2021 ◽  
pp. 10.1212/WNL.0000000000012534
Author(s):  
Seong Ho Jeong ◽  
Hye Ryun Kim ◽  
Jeonghun Kim ◽  
Hankyeol Kim ◽  
Namki Hong ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mmse Score ◽  
Dipeptidyl Peptidase ◽  
Cognitive Outcome ◽  
Diabetic Patients ◽  
Carrier Status ◽  
Amyloid Pet ◽  
Amyloid Burden ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors

Objectives:To investigate whether dipeptidyl peptidase-4 inhibitors (DPP-4i) have beneficial effects on amyloid aggregation and longitudinal cognitive outcome in diabetic Alzheimer’s disease-related cognitive impairment (ADCI).Methods:We retrospectively reviewed 282 patients with ADCI who had positive scan of 18F-florbetaben amyloid PET images were classified into three groups according to a prior diagnosis of diabetes and DPP-4i use: diabetic patients being treated with (ADCI-DPP-4i+, n=70) or without DPP-4i (ADCI-DPP-4i-, n=71), and non-diabetic patients (n=141). Multiple linear regression analyses were performed to determine inter-group differences in global and regional amyloid retention using standardized uptake value ratios calculated from cortical areas. We assessed the longitudinal changes in Mini-Mental State Examination (MMSE) score using a linear mixed model.Results:The ADCI-DPP-4i+ group had lower global amyloid burden than the ADCI-DPP-4i− group (β = 0.075, SE = 0.024, p = 0.002) and the non-diabetic ADCI group (β = 0.054, SE = 0.021, p = 0.010) after adjusting for age, sex, education, cognitive status, and APOE ε4 carrier status. Additionally, the ADCI-DPP-4i+ group had lower regional amyloid burden in temporo-parietal areas than either the ADCI-DPP-4i− group or the non-diabetic ADCI group. The ADCI-DPP-4i+ group showed a slower longitudinal decrease in MMSE score (β = 0.772, SE = 0.272, p = 0.005) and memory recall sub-score (β = 0.291, SE = 0.116, p = 0.012) than the ADCI-DPP-4i− group.Conclusions:These findings suggest that DPP-4i use is associated with low amyloid burden and favorable long-term cognitive outcome in diabetic patients with ADCI.

scholarly journals Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study

2014 ◽  
Vol 51 (6) ◽  
pp. 1015-1023 ◽  
Author(s):  
Seoyoung C. Kim ◽  
Robert J. Glynn ◽  
Jun Liu ◽  
Brendan M. Everett ◽  
Allison B. Goldfine
Keyword(s):  
Type 2 Diabetes ◽  
Cohort Study ◽  
Cardiovascular Events ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors
Sign in / Sign up

Export Citation Format

Share Document